Functional tumor specific CD8 + T cells in spleen express a high level of PD-1

Area of Science:

• Immunology
• Cancer Research
• Vaccinology

Background:

• Programmed cell death 1 (PD-1) receptor signaling inhibits T cell activity.
• PD-1's inhibitory role is primarily studied at the tumor site, with limited understanding of its function in lymphoid tissues.
• T cell activation can rapidly upregulate PD-1 expression in lymphoid tissues.

Purpose of the Study:

• To investigate the location where PD-1 signaling exerts its inhibitory function in tumor-bearing hosts.
• To assess the impact of PD-1 on vaccine-induced activation of splenic CD8+ T cells in mice.
• To evaluate the combined effect of PD-1 blockade and peptide vaccination on anti-tumor immunity.

Main Methods:

• Mice were immunized with a CD8+ T cell epitope peptide vaccine and poly IC.
• Splenic and tumor tissues were analyzed post-vaccination using flow cytometry to detect IFN-γ synthesis and PD-1 expression on CD8+ T cells.
• PD-1 blockade was administered to assess its effect on T cell activation and anti-tumor efficacy.

Main Results:

• Vaccination successfully activated splenic CD8+ T cells, evidenced by IFN-γ production upon peptide encounter.
• Activated splenic CD8+ T cells exhibited high PD-1 expression, correlating positively with IFN-γ synthesis.
• PD-1 blockade did not impede splenic CD8+ T cell activation but enhanced vaccine anti-tumor effects, increasing CD8+ tumor-infiltrated lymphocytes (TILs).

Conclusions:

• The PD-1 pathway primarily exerts its inhibitory function at the tumor site in tumor-bearing hosts.
• PD-1 expression on splenic CD8+ T cells correlates with their IFN-γ production capacity.
• Combining peptide vaccines with PD-1 blockade offers a synergistic approach to enhance anti-tumor immunity through increased CD8+ TILs.